Screening for ovarian cancer

Urban, Nicole

doi:10.1136/bmj.319.7221.1317

Cited by 13 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the low prevalence of ovarian cancer in the general population, it is estimated that a good clinical trial to develop a screening paradigm for ovarian cancer would require recruitment of >150,000 women [ 30 , 36 ]. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) accrued a total of 202,638 post-menopausal women between 2001 and 2005 [ 37 ].…”

Section: Ca125 As a Clinical Biomarkermentioning

confidence: 99%

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

et al. 2014

View full text Add to dashboard Cite

Over three decades have passed since the first report on the expression of CA125 by ovarian tumors. Since that time our understanding of ovarian cancer biology has changed significantly to the point that these tumors are now classified based on molecular phenotype and not purely on histological attributes. However, CA125 continues to be, with the recent exception of HE4, the only clinically reliable diagnostic marker for ovarian cancer. Many large-scale clinical trials have been conducted or are underway to determine potential use of serum CA125 levels as a screening modality or to distinguish between benign and malignant pelvic masses. CA125 is a peptide epitope of a 3–5 million Da mucin, MUC16. Here we provide an in-depth review of the literature to highlight the importance of CA125 as a prognostic and diagnostic marker for ovarian cancer. We focus on the increasing body of literature describing the biological role of MUC16 in the progression and metastasis of ovarian tumors. Finally, we consider previous and on-going efforts to develop therapeutic approaches to eradicate ovarian tumors by targeting MUC16. Even though CA125 is a crucial marker for ovarian cancer, the exact structural definition of this antigen continues to be elusive. The importance of MUC16/CA125 in the diagnosis, progression and therapy of ovarian cancer warrants the need for in-depth research on the biochemistry and biology of this mucin. A renewed focus on MUC16 is likely to culminate in novel and more efficient strategies for the detection and treatment of ovarian cancer.

show abstract

Section: Ca125 As a Clinical Biomarkermentioning

confidence: 99%

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Therefore, a specificity of 99.6% is required to achieve a positive predictive value of 10%, i.e., to limit the number of unnecessary surgical procedures to 10 for each case of cancer detected. 5 A specificity lower than this is likely to be unacceptable in this population, although may be acceptable to those with a positive family history of breast or ovarian cancer.…”

Section: Difficulties In Ovarian Cancer Screeningmentioning

confidence: 95%

Screening for Ovarian Cancer by Different Modes of Transvaginal Sonography

Prka¹,

Kurjak²

2009

Donald School Journal of Ultrasound in Obstetrics and Gynecology

View full text Add to dashboard Cite

Studies indicate that 3D power Doppler imaging can improve the ability to differenti ate benign from malignant ovarian masses, increasing significantly specificity and positive predictive value (PPV) in ovarian cancer detec tion. Therefore, the problem of low PPV in ultrasound-only strategies may be solved by introducing new 3D ultrasound technologies, used together in a secondary screening procedure. The possible role of 3D ultrasound and 3D power Doppler imaging in the early and accurate detection of ovarian cancer is under evaluation through Zagreb Ovarian Cancer Screening Trial.

show abstract

“…to limit the number of unnecessary surgical procedures to 10 for each case of cancer detected. 13 A specificity lower than this is likely to be unacceptable in the general population, although it may be acceptable to those with a positive family history of breast or ovarian cancer.…”

Section: Difficulties In Ovarian Cancer Screeningmentioning

confidence: 99%

Screening for Ovarian Cancer: The Possible Improvement by 3D Ultrasound and 3D Power Doppler

Prka¹,

Honemeyer²

2010

Donald School Journal of Ultrasound in Obstetrics and Gynecology

View full text Add to dashboard Cite

In developed countries more women die annually from ovarian cancer than from all other gynecologic malignancies combined. The fact that the ovaries are deep within the pelvic cavity and difficult to palpate is an obstacle to early diagnosis, especially in peri-post menopausal women, the group with the highest incidence of the disease. Seventy percent of patients are not diagnosed with the disease until the cancer has metastasized beyond the ovaries and is at stage 3 or 4. Patients with stage 3 or 4 have a 5-year survival rate of only 20-30%. Given the burden of suffering associated with ovarian cancer and the clear survival gradient related to the stage of disease at diagnosis, there is great need for development of effective screening methods for early detection of epithelial ovarian cancer. Better understanding of ovarian cancer etiology and increasing knowledge of tumor biology have both contributed to identify efficient Serum Tumor Markers, to screen high-risk populations. Technical advances in the field of ultrasound made transvaginal sonography (TVS) become the most important diagnostic tool, and multimodal (Serum markers plus TVS) screening appears to be a diagnostic break-through in fighting ovarian cancer. Five case reports illustrate that new ultrasound technologies such as 3D volume acquisition and 3D power Doppler imaging promise more reliable identification of an abnormal ovarian tumor vascularity and tumor-typical vascular architecture, thus facilitating early stage 1 -detection of the disease.

show abstract

Screening for ovarian cancer

Cited by 13 publications

References 13 publications

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

Screening for Ovarian Cancer by Different Modes of Transvaginal Sonography

Screening for Ovarian Cancer: The Possible Improvement by 3D Ultrasound and 3D Power Doppler

Contact Info

Product

Resources

About